Digital Medicine Society
The Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe) is a collaborative community with the FDA’s Center for Devices and Radiological Health (CDRH).
The Digital Health Measurement Collaborative Community (DATAcc) by the Digital Medicine Society (DiMe) has expanded the DATAcc by DiMe’s Library of Digital Measurement Products capabilities. The expansion, made in partnership with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and the Critical Path Institute’s (C-Path) Critical Path for Parkinson’s (CPP) consortium, includes digital solutions specifically for Parkinson’s disease research and care.
Following these latest developments, the Library now has four key areas: sleep, Alzheimer’s disease and related dementias (ADRD), physical activity, and Parkinson’s disease. Further expansions are expected in the future.
“Broad adoption of high-quality, fit-for-purpose digital measurement products promises to speed the inclusive development of new PD therapies, improve access to PD trials and specialist care by supporting decentralised and virtual research and care models, support earlier diagnoses, and improve outcomes through the identification of digital phenotypes,” said Jennifer Goldsack, CEO of DiMe. “By adding a comprehensive list of evidence-based PD tools to DiMe's rich and robust library, this collaboration has made it easier for the research community to benchmark progress in PD against other therapeutic areas, eliminating redundant development and identifying unmet need for new measurement products.”
The role that digital measurement technologies have in enabling the early diagnosis, development of novel treatments, and the delivery of care to patients, regarding Parkinson’s disease is only increasing. The Library aims to help equip clinicians, researchers, and developers with validated tools to allow them to monitor the disease in real-world settings and gain valuable insights.
“With Parkinson's disease, there is a lot of territory yet to be explored in terms of meaningful aspects of disease that can be measured with digital health technology. By leveraging the collective knowledge of all those working in the field, we can advance research more quickly to improve the lives of those with PD,” said Yuge Xiao, Clinical Research Lead at the MJFF. “The release of this centralised, open-source resource is a critical step forward for clinicians, developers, or researchers looking for evidence-based tools. The data sets give users the information needed to expedite timelines, facilitate assessment of the landscape for sensor-based digital health technologies, and allow benchmarking of digital innovation in PD to other related therapeutic areas, which was previously inaccessible.”
Diane Stephenson, CPP Executive Director at C-Path concludes, “Designing patient-centric digital interventions for PD requires a comprehensive understanding of the full patient experience. However, the diverse and fluctuating symptoms of PD present challenges in clinical monitoring. Sensor-based digital health technologies can bridge this gap by enabling remote and frequent measurement of PD symptoms, supporting early intervention, innovative treatments, and improved outcomes for patients. Collaborative approaches to collecting and cataloguing this information, and making it broadly accessible, will help advance the field in unprecedented ways.”